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Michiko Mori1, Cecilia K Andersson2, Gerard J Graham3, Claes-Göran Löfdahl2 and Jonas S Erjefält1,2*Abstract
Background: De novo lymphatic vessel formation has recently been observed in lungs of patients with moderate
chronic obstructive pulmonary disease (COPD). However, the distribution of lymphatic vessel changes among the
anatomical compartments of diseased lungs is unknown. Furthermore, information regarding the nature of
lymphatic vessel alterations across different stages of COPD is missing. This study performs a detailed morphometric
characterization of lymphatic vessels in major peripheral lung compartments of patients with different severities of
COPD and investigates the lymphatic expression of molecules involved in immune cell trafficking.
Methods: Peripheral lung resection samples obtained from patients with mild (GOLD stage I), moderate-severe
(GOLD stage II-III), and very severe (GOLD stage IV) COPD were investigated for podoplanin-immunopositive
lymphatic vessels in distinct peripheral lung compartments: bronchioles, pulmonary blood vessels and alveolar
walls. Control subjects with normal lung function were divided into never smokers and smokers. Lymphatics were
analysed by multiple morphological parameters, as well as for their expression of CCL21 and the chemokine
scavenger receptor D6.
Results: The number of lymphatics increased by 133% in the alveolar parenchyma in patients with advanced COPD
compared with never-smoking controls (p < 0.05). In patchy fibrotic lesions the number of alveolar lymphatics
increased 20-fold from non-fibrotic parenchyma in the same COPD patients. The absolute number of lymphatics
per bronchiole and artery was increased in advanced COPD, but numbers were not different after normalization to
tissue area. Increased numbers of CCL21- and D6-positive lymphatics were observed in the alveolar parenchyma in
advanced COPD compared with controls (p < 0.01). Lymphatic vessels also displayed increased mean levels of
immunoreactivity for CCL21 in the wall of bronchioles (p < 0.01) and bronchiole-associated arteries (p < 0.05), as
well as the alveolar parenchyma (p < 0.001) in patients with advanced COPD compared with never-smoking
controls. A similar increase in lymphatic D6 immunoreactivity was observed in bronchioles (p < 0.05) and alveolar
parenchyma (p < 0.01).
Conclusions: This study shows that severe stages of COPD is associated with increased numbers of alveolar
lymphatic vessels and a change in lymphatic vessel phenotype in major peripheral lung compartments. This novel
histopathological feature is suggested to have important implications for distal lung immune cell traffic in
advanced COPD.
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Chronic obstructive pulmonary disease (COPD) is a
chronic, inflammatory lung disease with increased mor-
tality and morbidity [1]. Long-term smoke exposure is
the primary cause for developing COPD. The inflamma-
tory reactions of airways, pulmonary vasculature, and al-
veolar parenchyma are related to both innate and
adaptive immune responses [2-5]. For example, several
studies have revealed increased numbers of lymphocytes
[6,7], mast cells [8], dendritic cells [9,10], and ectopic
lymphoid aggregates in peripheral lungs of patients with
COPD [11-13].
The lymphatic vessels are, apart from their role in
interstitial fluid homeostasis, critical for transporting
antigen-loaded dendritic cells and memory/effector T-
cells to draining lymph nodes where they initiate
adaptive immune responses [14-16]. Recent studies
suggest that naïve T-cells are also transported to
lymph nodes via lymphatic vessels [17]. It is also likely
that lung lymphatic vessels transport leukocytes to the
ectopic lymphoid aggregates in COPD lungs.
The entry of antigen-loaded dendritic cells into lym-
phatic vessels and their migration to draining lymph
nodes is regulated by the homeostatic CC chemokine
ligand CCL21, also known as secondary lymphoid che-
mokine, which is secreted by the lymphatic endothelial
cells and binds to its receptor (the CC chemokine re-
ceptor CCR7) on activated dendritic cells [18-21]. The
lymphatic endothelium also expresses the chemokine
scavenger receptor D6, which binds and degrades in-
flammatory CC chemokines [22-24]. Thus, D6 clears
the lymphatic endothelial surface of inflammatory che-
mokines to maintain the chemoattractant gradient of
CCL21 and facilitate the migration of CCR7-positive
immune cells to lymph nodes [25].
Lymphatic vessels have been implicated in several
pathological conditions of the lung. Formation of new
lymphatic vessels (i.e. lymphangiogenesis) has been
described in patients with lymphangioleiomyomatosis
[26] and interstitial lung diseases, including idiopathic
pulmonary fibrosis (IPF) [27] and diffuse alveolar
damage [28]. In contrast, reduced number of lymph-
atic vessels has been reported in airways of patients
who died of severe asthma [29]. Recent observations
that lymphatics are closely associated with pulmonary
sarcoid granulomas [30,31] further support a general
involvement of lymphatic vessels in pulmonary dis-
eases. In a mouse model of chronic airway inflam-
mation, Mycoplasma pulmonis infection resulted in
airway lymphangiogenesis which was mediated by
VEGF-C and VEGF-D producing leukocytes [32]. In the
same model, inhibition of lymphangiogenesis resulted in
mucosal oedema. Only one previous study has been
performed in patients with COPD [33]. This study byHardavella et al. [33] provides an important indication
that lymphatic vessels are more numerous in patients with
moderate COPD. However, it remains unknown to what
extent the lymphatic system is increased in patients with
other severities of COPD. Other remaining questions
concern the distribution of lymphatic vessel changes
among the different compartments of the peripheral lung
and whether the lymphatic endothelium has been pheno-
typically altered.
The aim of this study is to perform a detailed mor-
phometric characterization of lung lymphatic vessels
in patients with different severities of COPD and to
assess disease-related changes across distinct periph-
eral lung compartments where the lymphatics have
remained poorly studied; i.e. bronchioles, pulmonary
arteries and alveolar parenchyma. Additional focus is
on the lymphatic expression of key molecules involved
in immune cell trafficking.Methods
Patients and lung tissue collection
Lung resection specimens were obtained from never
smokers, smokers and patients with GOLD stage I-III
COPD undergoing therapeutic lung resection surgery
for bronchial tumour. Only patients with well-
delineated solitary tumours were included in the
study. Care was taken to collect peripheral lung tis-
sue as far from the tumour as possible to avoid can-
cer tissue in any of the sections, a procedure that
repeatedly has been used to collect lung tissue sam-
ples [8,10,34]. Explant lungs from GOLD stage IV
COPD patients, who lacked any history of lung can-
cer, were collected during lung transplantation sur-
gery at Skåne University Hospital, Lund, Sweden. At
the time of surgery, all patients were free from ex-
acerbation. The tissue samples used in this study
have, in part, been described in our previous publica-
tions [8,12]. Severity of COPD was classified accord-
ing to GOLD criteria [1]. Patients with COPD (n = 27)
were divided into three subgroups: patients with mild
(GOLD stage I), moderate-severe (GOLD stage II-III)
and very severe (GOLD stage IV) COPD. Non-COPD
control subjects (n = 14) were divided into never
smokers and ex-/current smokers without COPD. For
more detailed subject characteristics, see Table 1. For
each patient, peripheral tissue samples from randomly
selected lobes were immersed into 4% buffered parafor-
maldehyde immediately after surgical excision and mul-
tiple paraffin-embedded tissue blocks were prepared for
histological analysis. This study was approved by the
Swedish Research Ethics Committee in Lund. All pa-
tients signed informed consent to participate in the
study.
Table 1 Characteristics of the study subjects
Parameters Never smokers Smokers w/o COPD GOLD I COPD GOLD II-III * COPD GOLD IV COPD Overall
p-value
Subjects, n 8 6 6 11 10
Gender, male/female 2/6 3/3 4/2 9/2 4/6
Age, years 66 (33–76) # 55 (47–68) 68 (56–75) 73 (61–77) † 62 (53–66) § <0.01
Height, m 1.6 (1.5-1.8) 1.8 (1.6-1.8) 1.8 (1.6-1.8) 1.7 (1.6-1.9) 1.7 (1.5-1.9) 0.247
Body mass index, kg/m2 22.6 (19.8-29.7) 22.2 (19.7-26.6) 23.1 (20.3-26.8) 25.3 (17.7-33.3) 22.9 (18.0-27.2) 0.462
Smoking history, pack-years 0 40 (20–80) 39 (25–66) 47 (16–65) 43 (25–60) 0.783
Smoking status, ex-smokers/current NA 3/3 3/3 8/3 10/0
FEV1, L 2.5 (1.7-5.1) 3.1 (1.9-3.5) 2.9 (1.6-3.2) 1.8 (1.2-2.3) 0.6 (0.4-1.0) <0.001
FEV1/(F)VC, % 82 (66–121) 78 (71–88) 67 (65–70) 53 (41–67)
≠ 32 (20–39) <0.001
FEV1, % of predicted 109 (82–141) 93 (82–120) 86 (80–95) 64 (43–74)
≠ 23 (15–27) <0.001
Inhaled β2-agonists
Short-acting (yes/no/unknown) 0/8/0 0/6/0 1/5/0 2/9/0 4/5/1‡
Long-acting (yes/no/unknown) 0/8/0 0/6/0 0/6/0 0/11/0 4/5/1‡
Inhaled anticholinergics
Short-acting (yes/no/unknown) 0/8/0 0/6/0 1/5/0 2/9/0 3/6/1‡
Long-acting (yes/no/unknown) 0/8/0 0/6/0 0/6/0 0/11/0 5/4/1‡
Inhaled short-acting β2-agonist plus anticholinergics
(yes/no/unknown)
0/8/0 0/6/0 0/6/0 0/11/0 3/6/1‡
Corticosteroids
Inhaled (yes/no/unknown) 0/8/0 0/6/0 0/6/0 1/10/0 2/7/1‡
Oral (yes/no/unknown) 0/8/0 0/6/0 0/6/0 0/11/0 2/7/1‡
Inhaled long-acting β2-agonist plus corticosteroids (yes/no/unknown) 0/8/0 0/6/0 0/6/0 1/10/0 7/2/1
‡
Mucolytics (yes/no/unknown) 0/8/0 0/6/0 2/4/0 0/11/0 5/4/1‡
Values are median (range) or n. Statistical analysis was performed using Kruskal-Wallis nonparametric test followed by Dunn's multiple comparison post-test. COPD: chronic obstructive pulmonary disease; FEV1: forced
expiratory volume in one second; (F)VC: (forced) vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; NA: not applicable.
*: Two patients with GOLD stage III COPD (median value of FEV1 % of predicted, 44.5%; range 43.2-45.9).
#: The mean value of the study group is 63 years.
‡: One patient with unknown medical history.
†: p < 0.01 vs. smokers without COPD.
§: p < 0.05 vs. patients with GOLD stage II-III COPD.
: p < 0.001 vs. never smokers.
: p < 0.001 vs. smokers without COPD.
⁪ : p < 0.01 vs. patients with GOLD stage I COPD.
≠: p < 0.01 vs. never smokers.
: p < 0.05 vs. patients with GOLD stage I COPD.
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Validation of markers for proper identification of human
lung lymphatic vessels
Since there are still some remaining questions regarding
the suitability of lymphatic markers to specifically detect
lung lymphatic vessels, an initial aim was to validate the
specificity of common antibodies against lymphatic
endothelial cells. For this purpose we initiated our study
with a careful evaluation of the previously published
lymphatic vessel markers LYVE-1, podoplanin (D2-40),
and Prox1 for their capacity to distinguish lung lymphatic
vessels from pulmonary blood vessels (some of which are
known to express lymphatic vessel markers [35]).
Protocols for immunohistochemistry
Four-micron-thick paraffin-embedded sections were
heated at 60°C for 20 min, and then subjected to
simultaneous dewaxing and antigen retrieval accordingTable 2 Primary antibodies used for immunohistochemistry
Antigen Clone * Supplier
CD8 C8/144B Dako, Glostrup, Den
CD11c 5D11 Novocastra/Leica, N
Upon Tyne, UK
CD20 L26 Dako
CD57 NK1 Novocastra/Leica
CD68 PG-M1 Dako
Chemokine ligand 21 (CCL21) Goat polyclonal R&D Systems, Abing
Chemokine scavenger
receptor D6
Made in-house [23] Provided by Dr. G.J
Ki-67 Rabbit polyclonal Biocare Medical, Co
Lymphatic vessel endothelial
hyaluronan receptor-1 (LYVE-1)
Rabbit polyclonal Abcam, Cambridge
Podoplanin D2-40 Biocare Medical
Prospero-related homeobox
transcription factor (Prox1)
Rabbit polyclonal Abcam
α-smooth muscle actin (α-SMA) 1A4 Sigma-Aldrich,
Saint Louis, MO, US
PC: pressure cook, 2100 Retriever, Prestige Medical Ltd., Blackburn, England; PT: pre
*: Mouse monoclonal antibodies unless otherwise stated.
#: DIVA Decloaker, pH 6, DV2004 MX, Biocare Medical.
‡: EnVision™ FLEX Target Retrieval Solution, pH 9, K8004, Dako.to Table 2. All staining procedures were performed
in an automated slide stainer (Autostainer Plus,
DakoCytomation, Glostrup, Denmark). Primary anti-
bodies used are listed in Table 2.
Single staining immunohistochemistry for LYVE-1 was
performed using EnVision Peroxidase/Dab Detection Sys-
tem kit (Rabbit/mouse K5007, Dako, Glostrup, Denmark).
Endogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide. After incubation with rabbit anti-
human LYVE-1 polyclonal antibodies for 1h, sections
were incubated with Polymer/HRP-linked secondary
antibodies. Next, sections were incubated with 3,3’-
diaminobenzidine (Dab) substrate solution for 10 min,
counterstained with Mayer’s haematoxylin, dehydrated
through ethanol series, cleared in xylene and mounted
with Pertex (HistoLab, Gothenburg, Sweden).
Double staining immunohistochemistry was performed
using EnVision G|2 Doublestain System (K5361, Dako).Antigen
retrieval
Dilution Against
mark Low pH # 1:640 Cytotoxic T-cells
PC
ewcastle Low pH # 1:100 Myeloid dendritic cells
and macrophages
PC
Low pH # 1:1200 B-cells
PC
Low pH # 1:200 Natural killer cells and
T-cell subsets
PC
Low pH # 1:600 Monocytes and macrophages
PC
don, UK High pH‡ 1:3000 Lymphatic endothelium
PT
. Graham High pH‡ 1:400 Lymphatic endothelium,
leukocytes
PT
ncord, CA, USA Low pH # 1:200 Cell proliferation
PC
, UK Low pH # 1:400 Lymphatic endothelium
PC
Low pH # 1:100 Lymphatic endothelium
PC
High pH‡ 1:800 Lymphatic endothelial
cell nuclei
PT
A
Low pH # 1:1000 Smooth muscle cells
PC
-treatment module, Dako, Glostrup, Denmark.
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phosphatase activity, sections were incubated with anti-
bodies directed against Prox1 or podoplanin for 1 h.
Next, sections were incubated with Polymer/HRP-linked
secondary antibodies followed by Dab substrate solution
for 10 min. An additional blocking step with Dako Double
Stain Blocking Reagent was performed to prevent add-
itional binding of secondary antibodies to the first primary
antibodies. Sections were then incubated with antibodies
against podoplanin, CD8, CD11c, CD20, CD57, or CD68
for 1 h. Finally, sections were incubated with Polymer/AP-
linked secondary antibodies, Dako Liquid Permanent Red
substrate solution for 10 min, counterstained with Mayer’s
haematoxylin, and mounted with Pertex.
Double staining immunohistochemistry for Prox1 and
CCL21 or Prox1 and D6 was performed using an
Avidin-Biotin/Streptavidin detection system. Sections
were stained with rabbit anti-human Prox1 polyclonal
antibodies using the protocol described for LYVE-1.
After incubation with Dab substrate solution, sections
were blocked with a denaturating solution (DNS001H,
L, Biocare Medical, Concord, CA, USA) to prevent add-
itional binding to the first primary antibody. Endogenous
alkaline phosphatase activity was blocked with Dako
Dual Enzyme Block (S2003). Sections were then incu-
bated with Dako Protein Block Serum Free (X0909) and
an additional blocking with Dako Avidin/Biotin Blocking
solution (X0590) was performed. After incubation with
antibodies against goat anti-human CCL21 or mouse anti-
human D6, sections were incubated with biotinylated
rabbit anti-goat (1:200, BA-1000, Vector Laboratories,
Inc., Burlingame, CA, USA) or biotinylated horse anti-
mouse IgG secondary antibodies (1:200, BA-2000,
Vector Laboratories). Next, sections were incubated
with Streptavidin-AP (1:100, D0396, Dako) and immu-
noreactivity was detected with Dako Liquid Permanent
Red substrate solution (K0640). Finally, sections were
counterstained with Mayer’s haematoxylin and mounted
with Pertex.
Double staining immunohistochemistry for podoplanin
and α-smooth muscle actin (α-SMA) was performed as
described previously [12].
Immunostaining for podoplanin as well as CCL21
and D6 was performed in batches containing sections
from control subjects and patients with COPD to
avoid variations in staining intensity.
Quantitative assessments of lymphatic vessels
To compare the anatomical distribution of lymphatic
vessels among the study groups, tissue blocks containing
bronchioles (non-cartilaginous, < 2 mm in cross-sectional
internal diameter), pulmonary blood vessels, as well as al-
veolar parenchyma were included in the study. Thus, se-
verely emphysematous tissue blocks, lacking bronchiolesor pulmonary arteries, were excluded. A total of 62 tissue
blocks (two blocks per subject) from control subjects and
patients with GOLD stage I-III COPD and 30 large blocks
(three blocks per subject) from patients with GOLD stage
IV COPD was examined. In total 10 743 individual cross-
sectioned lymphatic vessels were analysed across the study
groups (total number of analysed lymphatic vessels in all
tissue blocks were as follows: never smokers, 1457;
smokers, 1034; GOLD stage I, 891; GOLD stage II-III,
1739; GOLD stage IV, 5622). For each section high-
resolution digital images of whole lung tissue area were
generated using a slide-scanning robot (ScanScope, Aperio
Technologies, Vista, CA, USA). Morphometric and immu-
nohistochemical measurements were performed on the
generated digital images using Aperio ImageScope V.10.0
Image Analysis Software (Aperio Technologies). All quan-
tifications were carried out on blinded sections.
On each section, all visible bronchioles and bronchiole-
associated arteries, as well as multiple solitary blood
vessels (at a distance from visible bronchioles and
bronchiole-associated arteries) and large areas of al-
veolar tissue (at a distance from visible bronchioles,
arteries, arterioles and veins) were investigated for the
presence of podoplanin-immunopositive lymphatic ves-
sels. The pleura or intra-lobular septa were not visible in
all sections and, therefore, were excluded from the ana-
lysis. The area of the subepithelial tissue was measured by
cursor tracing the region extending from the basement
membrane to the parenchyma (i.e. the entire wall under
the epithelium). The area of the adventitial layer of
bronchiole-associated arteries was measured by manually
tracing the region extending from the outer border of the
tunica media to the alveolar parenchyma. Regions of
non-emphysematous and non-fibrotic alveolar tissue
were delineated (excluding bronchioles and blood
vessels) and the pixels corresponding to the alveolar
tissue (excluding airspaces) were counted and expressed
as square mm of alveolar parenchyma. Solitary blood
vessels were subdivided according to their mean
cross-sectional internal lumen diameter, which was
calculated by dividing the sum of the minimal and
maximal endothelium-to-endothelium distance by two.
The following subdivision was performed: <50 μm in
mean diameter, 50–100 μm in mean diameter and >100
μm in mean diameter. The perimeter of each lymphatic
vessel was delineated by cursor tracing along the lymph-
atic endothelium by freehand. To allow for a more
complete picture of the nature of changes of the lymphatic
vessels, these were analysed by four complementary pa-
rameters as described below.
Accumulated lymph vessel endothelial length per tissue area
The accumulated lymphatic vessel endothelial length,
calculated as the total sum of all lymphatic vessel
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olar subepithelial tissue, arterial adventitia or alveolar
tissue.Accumulated lymph vessel endothelial length per
bronchiole or pulmonary vessel
The total sum of all lymph vessel perimeters was calcu-
lated and data were expressed as the accumulated lymph
vessel endothelial length per bronchiole, bronchiole-
associated artery and solitary blood vessel. In addition,
in bronchioles, the accumulated lymph vessel endothelial
length was normalized to the length of the basement
membrane perimeter.
Numbers of lymphatic vessels per tissue area
The numbers of lymphatic vessels in each analysed
tissue region were counted and data were normalized to
the area of the bronchiolar subepithelial tissue, arterial
adventitia, and alveolar tissue.Figure 1 Staining characteristics of immunohistochemical markers for
immunoreactivity was present on vessels with (A) lymphatic morphology (
Double staining immunohistochemistry for podoplanin (brown, arrowhead
immunoreactivity on lymphatic vessels and not on α-SMA-positive blood v
(red) and Prox1 (brown nuclei, exemplified by arrowhead). Ep, bronchiolar
with Mayer’s haematoxylin (blue stain). Black endogenous pigment deposi
(F) 25 μm.Numbers of lymphatic vessels per bronchiole or pulmonary
vessel
The numbers of lymphatic vessels were expressed per
bronchiole, bronchiole-associated artery, and solitary
blood vessel. In bronchioles, the numbers of lymph ves-
sels were also normalized to the length of the basement
membrane perimeter.Quantitative assessments of lymphatic CCL21 and D6
expression
Immunoreactivity for lymphatic CCL21 and D6 was
quantified in the endothelium of Prox1-immunopositive
lymphatic vessels in tissue sections from never-smoking
controls and patients with GOLD stage IV COPD.
The outer perimeter of the lymphatic endothelium
was delineated and a fixed threshold for identification
of red positive staining was set in order to only calculate
the number of pixels corresponding to CCL21 or D6
immunoreactivity (Aperio Positive Pixel Count Algorithmdetection of lymphatic vessels in the peripheral lung. LYVE-1
brown, arrowheads) and (B) blood vessel morphology (brown). (C-E)
s) and α-smooth muscle actin (α-SMA, red) revealed podoplanin-
essels (V). (F) Double staining immunohistochemistry for podoplanin
epithelium; LA, lymphoid aggregate. All sections were counterstained
tion is visible in (A-C). Scale bars: (A-C, E) 50 μm; (D) 100 μm;
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immunoreactivity (brown colour) were automatically ex-
cluded in the analysis. Data were expressed as lymphatic
CCL21 or D6 immunoreactivity per unit area of tissue or
per lymphatic vessel perimeter.
Statistics
Statistical analysis was performed using GraphPad Prism
V.5.0 (GraphPad software, San Diego, CA, USA). Kruskal-
Wallis nonparametric test followed by Dunn’s multiple
comparisons post-test was used for comparison between
all study groups and Mann–Whitney rank sum test for
comparison between two groups. A p value <0.05 was
considered significant.
Results
Podoplanin is a suitable marker for lung lymphatic
vessels
In initial studies antibodies against LYVE-1 and pod-
oplanin were evaluated for proper identification of
lymphatic vessels in routine paraffin-embedded human
lung sections. Immunoreactivity for both markers was
detected on vessels with an irregular endothelial mor-
phology, thin vessel wall, and sometimes barely visible
lumen (Figure 1A and 1C). Whereas LYVE-1 immunore-
activity was occasionally detected also on scattered
blood vessels (Figure 1B), podoplanin was restricted to
vessels that lacked immunoreactivity for blood vessel-
associated α-SMA (Figure 1C-E). Co-expression analysis
of podoplanin and Prox1, a transcription factor ex-
pressed in lymphatic endothelial cell nuclei, further con-
firmed podoplanin-positive vessels to be true lymphatic
vessels (Figure 1F). In addition to lymphatic vessels,
weak immunoreactivity for podoplanin was detectable
on Type I pneumocytes (exemplified in Figure 1D-E
and Figure 2A-C) and epithelial basal cells (exempli-
fied in Figure 2A). However, this non-lymphatic stain-
ing could easily be excluded in our quantification and
assessment of lymphatics. Hence, podoplanin was used
for further detection of lung lymphatic vessels.
Localization of lymphatic vessels in peripheral lung
compartments
In all study groups, lymphatic vessels were present in
the wall of bronchioles and bronchiole-associated arteries,
as well as in the region between a bronchiole and an artery
(i.e. bronchiolar-vascular bundle). In the bronchiolar wall,
lymphatic vessels were foremost present in the adventitia
layer and to a lesser extent in the lamina propria (exempli-
fied in Figure 2A). For all study groups, lymphatic vessels
in bronchiolar-vascular bundles generally had a greater
perimeter compared to lymphatics associated with the
subepithelial tissue. In agreement with previous studies in
the lung [36], the lymphatic vessels in bronchiole-associated arteries were restricted to the adventitia layer
(Figure 2B). Also, α-SMA-positive solitary blood ves-
sels (well-separated from bronchioles) were associated
with adventitial lymphatics (exemplified in Figure 1D-E).
Intra-alveolar lymphatic vessels, not associated with α-
SMA-positive blood vessels or any conducting airways,
were also found in all study groups (exemplified in
Figure 2C).
Differential lymphatic changes among peripheral lung
compartments in patients with advanced COPD
Bronchioles
In patients with GOLD stage IV COPD the accumulated
lymph vessel endothelial length in the subepithelial
tissue was significantly increased compared with never-
smoking and smoking control subjects (Figure 2E and
Table 3). Whereas the absolute numbers of lymphatic
vessels (expressed as lymphatic vessel numbers per
bronchiole or basement membrane perimeter) were
increased in patients with GOLD stage IV COPD
compared with never-smoking controls (Table 3), no
statistical differences were observed when numbers were
normalized to the unit area of the subepithelial tissue
(Figure 2H).
Bronchiole-associated arteries
The accumulated lymph vessel endothelial length per
artery was increased in patients with GOLD stage IV
COPD compared with never-smoking controls (Table 3).
However, no difference in the accumulated lymph vessel
endothelial length per unit adventitial area was observed
among the study groups (Figure 2F). Similarly, the lymph-
atic vessel numbers per artery was increased in patients
with GOLD stage IV COPD compared with never-
smoking controls and patients with GOLD stage I COPD
(Table 3), but the numbers per unit adventitial area was
not changed among the study groups (Figure 2I).
Alveolar parenchyma
Intra-alveolar lymphatic vessels were scarce in never-
smoking control subjects but increased both in terms of
accumulated lymph vessel endothelial length and lymph-
atic vessel numbers in patients with GOLD stage IV
COPD (Figure 2G and 2J). Moreover, two patients with
GOLD stage IV COPD had identifiable fibrotic lesions in
the alveolar parenchyma (exemplified in Figure 2D). A
separate analysis of these fibrotic regions revealed that
the numbers of lymphatic vessels were dramatically
increased compared to the surrounding non-fibrotic
alveolar tissue (Table 3).
Solitary pulmonary blood vessels
In α-SMA-positive solitary blood vessels, both the accu-
mulated lymph vessel endothelial length and lymphatic
Figure 2 (See legend on next page.)
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Figure 2 Increased number of lymphatic vessels in the alveolar compartment in patients with advanced COPD. (A-D) Immunohistochemical
staining for podoplanin (brown, arrowheads) and α-smooth muscle actin (α-SMA, red) in sections of a patient with GOLD stage IV COPD. Lymphatic
vessels are present in (A) bronchiolar (Br) subepithelial tissue, (B) adventitia of bronchiole-associated arteries (Ar), (C) alveolar parenchyma and
(D) patchy fibrotic lesions. Cell nuclei were counterstained with Mayer’s haematoxylin (blue stain). (E-G) Accumulated lymphatic vessel endothelial
length (i.e. the total sum of all lymphatic perimeters) in (E) bronchiolar subepithelial tissue, (F) adventitia of bronchiole-associated arteries and (G) non-
fibrotic alveolar parenchyma in never smokers, smokers without COPD and patients with COPD. (H-J) Number of lymphatic vessels in (H) bronchiolar
subepithelial tissue, (I) adventitia of bronchiole-associated arteries and (J) non-fibrotic alveolar parenchyma in never smokers, smokers without COPD
and patients with COPD. Statistical analysis was performed using Kruskal-Wallis nonparametric test and Dunn’s multiple comparison post-test.
Horizontal lines indicate median value. * p < 0.05; ** p < 0.01. Scale bars: (A) 200 μm; (B) 100 μm; (C) 50 μm; (D) 150 μm.
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diameter (Figure 3). In patients with GOLD stage IV
COPD, both the accumulated lymph vessel endothelial
length and numbers were increased in blood vessels of
<50 μm in diameter compared with never-smoking and
smoking control subjects (Figure 3A and 3D). A similar
increase in the accumulated lymph vessel endothelial
length was observed in patients with GOLD stage I
compared with never-smoking controls (Figure 3A). In
GOLD stage IV COPD, the accumulated lymph vessel
endothelial length and numbers further increased in
blood vessels of >100 μm in diameter compared with
never-smoking control subjects (Figure 3C and 3F).Table 3 Quantitative data on lymphatic vessel parameters
Parameters Never smokers Smokers w/
Bronchiole
Lymphatic vessel numbers per mm BM 1.91 4.09 *
(0.40-2.92) (3.11-6.
Lymphatic vessel numbers per bronchiole 3.13 5.33
(0.50-8.47) (3.00-10
Accumulated lymphatic vessel endothelial
length (mm) per mm BM
0.19 0.44
(0.04-0.68) (0.38-0.
Accumulated lymphatic vessel endothelial
length (mm) per bronchiole
0.58 0.67
(0.04-1.09) (0.31-0.
Bronchiole-associated artery
Lymphatic vessel numbers per artery 3.78 4.17
(0.50-8.50) (4.00-7.
Accumulated lymphatic vessel endothelial
length (mm) per artery
0.97 1.53
(0.11-3.32) (0.60-1.
Alveolar parenchyma
Lymphatic vessel numbers per mm2 fibrotic
parenchymal lesions
NA NA
Values are median (range). Statistical analysis was performed using Kruskal-Wallis n
COPD: chronic obstructive pulmonary disease; BM: basement membrane; GOLD: Glo
*: p < 0.01 vs. never smokers.
#: p < 0.01 vs. smokers without COPD.
§: p < 0.05 vs. patients with GOLD stage I COPD.
‡: Two patients with GOLD stage IV COPD.Importantly, in all lung compartments investigated
only scarce number of lymphatic vessels showed immu-
noreactivity for the proliferation marker Ki-67 (data not
shown).
Size distribution of lymphatic vessels in peripheral lung
compartments
No differences in mean perimeter of individual lymph-
atic vessels were observed among the study groups
(Figure 4A-C). Our assessment of thousands of indi-
vidual lymphatic vessels per compartment allowed a
detailed frequency analysis of the size distribution of
lymphatic vessels. This analysis revealed that on theo COPD GOLD I COPD GOLD II-III COPD GOLD IV COPD Overall
p-value
2.94 3.76 * 4.11 * <0.001
42) (2.13-6.78) (3.18-6.68) (2.18-5.23)
6.88 7.83 10.85 * <0.01
.78) (2.00-14.50) (4.00-13.00) (6.42-21.33)
0.54 0.50 0.75 * <0.01
56) (0.33-0.93) (0.30-0.87) (0.42-1.01)
1.05 0.80 1.94* # <0.001
94) (0.42-1.96) (0.41-1.91) (0.78-3.94)
3.50 5.50 8.07 * § <0.01
67) (2.80-9.00) (1.67-10.00) (4.10-10.11)
1.38 1.59 2.39 * <0.05
91) (0.95-2.90) (0.60-2.60) (1.39-4.66)
NA NA 117.8 ‡ -
(101.1-134.4)
onparametric test followed by Dunn's multiple comparison post-test.
bal Initiative for Chronic Obstructive Lung Disease; NA: not applicable.
Figure 3 Accumulated lymphatic endothelial length in solitary non-bronchiolar blood vessels. (A-C) Accumulated lymphatic vessel
endothelial length (i.e. the total sum of all lymphatic perimeters) and (D-F) number of lymphatic vessels associated with α-smooth muscle
actin-positive solitary blood vessels with a diameter of < 50 μm, 50–100 μm and >100 μm in never smokers, smokers and patients with COPD.
Statistical analysis was performed using Kruskal-Wallis nonparametric test and Dunn’s multiple comparison post-test. Horizontal lines indicate
median value. * p < 0.05; ** p < 0.01.
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among the patient cohorts (Figure 4D-F). In bronchi-
oles, however, there was a tendency for a shift towards
larger lymphatic vessel sizes in the COPD groups (that
in the 101 to 200 μm range also reached statistical signifi-
cance for patients with GOLD stages II-IV COPD; overall
p-value = 0.043) (Figure 4D). In bronchiole-associated
arteries and alveolar parenchyma, no such differences
in the lymphatic vessel size distribution were observed
(Figure 4E-F). This analysis also showed that lymph-
atic vessels in the alveolar parenchyma were generally
smaller than in bronchioles and associated arteries,
the latter compartment having the largest mean per-
imeter (Figure 4G).
Lymphatic vessels have an altered expression profile of
CCL21 and D6 in advanced COPD
Since lymphatic vessels were increased in numbers in
peripheral lungs of patients with advanced COPD we
next investigated if these changes were also associated
with altered lymphatic endothelial expression of molecules
known to regulate leukocyte entry into the lymphatics.
For this purpose we analysed the immunoreactivity forthe homeostatic leukocyte chemoattractant chemokine
CCL21 and the inflammatory chemokine scavenger re-
ceptor D6 on lymphatic vessels. The percentage of
CCL21-immunopositive vessels among total Prox1-
positive lymphatics was not changed in bronchioles and
bronchiole-associated arteries, but significantly increased
in the alveolar parenchyma in patients with GOLD
stage IV COPD compared with never-smoking controls
(Figure 5A). This was accompanied by increased abso-
lute numbers of CCL21-positive lymphatic vessels in al-
veolar walls (Figure 5B). Patients with COPD had also
increased percentages of D6-immunpositive vessels among
all Prox1-positive lymphatics in both bronchiole-
associated arteries and alveolar parenchyma (Figure 5C).
However, the absolute number of D6-immunopositive
lymphatic vessels was only increased in the alveolar paren-
chyma (Figure 5D). Immunostainings for lymphatic
CCL21 and D6 are exemplified in Figure 5E-G. Lung
lymphoid aggregates were also found to contain CCL21-
immunopositive lymphatic vessels (Figure 5F).
Next, we investigated the accumulated amount of lym-
phatic staining for CCL21 and D6. Patients with GOLD
stage IV COPD showed, compared with never-smoking
Figure 4 Lymphatic vessels display similar size distribution among the study groups. (A-C) Mean perimeter of individual lymphatic vessels
in (A) bronchiolar subepithelial tissue, (B) adventitia of bronchiole-associated arteries and (C) alveolar parenchyma in never smokers, smokers and
patients with COPD. Horizontal lines indicate median value. (D-F) Size distribution of individual lymphatic vessels in (D) bronchiolar subepithelial
tissue (n = 2491), (E) adventitia of bronchiole-associated arteries (n = 1169) and (F) alveolar parenchyma (n = 2073) in control subjects and patients
with COPD. Each point represents the median percentage of the number of lymphatic vessels within each specific vessel perimeter range.
(G) Size distribution of all lymphatic vessels in bronchiolar subepithelial tissue, adventitia of bronchiole-associated arteries and alveolar
parenchyma when study groups are combined. Each point indicates the mean, and error bars indicate SEM.
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CCL21 as well as D6 (expressed as the total amount of
lymphatic immunoreactivity per unit area) in bronchiolesand alveolar parenchyma (Figure 6A-B). Analysis of all in-
dividual Prox1-immunopositive lymph vessels revealed
that lymphatic CCL21 immunoreactivity (expressed as the
Figure 5 (See legend on next page.)
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Figure 5 Increased number of alveolar CCL21- and D6-positive lymphatic vessels in patients with advanced COPD. (A) Percentage of
CCL21-positive lymphatic vessels among all Prox1-positive lymphatics and (B) number of CCL21-positive lymphatic vessels in bronchiolar
subepithelial tissue, adventitia of bronchiole-associated arteries and alveolar parenchyma in never smokers and patients with GOLD stage IV
COPD. (C) Percentage of D6-positive lymphatic vessels among all Prox1-positive lymphatics and (D) number of D6-positive lymphatic vessels in
similar lung compartments as for (A and B) in never smokers and patients with GOLD stage IV COPD. Mann–Whitney rank sum test was used for
comparison between two groups. Horizontal lines indicate median value for each cohort. ** p < 0.01. (E and F) Immunohistochemical staining for
CCL21 (red) and Prox1 (brown nuclei) and (G) immunohistochemical staining for D6 (red) and Prox1 (brown nuclei) in sections of patients with GOLD
stage IV COPD. LA, lymphoid aggregate. Sections were counterstained with Mayer’s haematoxylin (blue stain). Scale bars: (E, G) 20 μm; (F) 30 μm.
Figure 6 Increased immunoreactivity for CCL21 and D6 in lymphatic endothelium in patients with advanced COPD. (A) Accumulated
lymphatic immunoreactivity of CCL21 and (B) D6 in bronchiolar subepithelial tissue, adventitia of bronchiole-associated arteries and alveolar
parenchyma in never smokers and patients with GOLD stage IV COPD. Each point indicates the total amount of lymphatic immunoreactivity per
unit area. (C) Immunoreactivity of CCL21 and (D) D6 per lymphatic vessel endothelial length in bronchiolar subepithelial tissue, adventitia of
bronchiole-associated arteries and alveolar parenchyma. (E and F) Scatter graphs representing the immunoreactivity for (E) CCL21 and (F) D6 in
each analysed lymphatic vessel in (C and D). Mann–Whitney rank sum test was used for comparison between two groups. Horizontal lines
indicate median value for each cohort. * p < 0.05; ** p < 0.01; *** p < 0.001.
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endothelial length) was increased in all lung compart-
ments; i.e. bronchioles, bronchiole-associated arteries, and
alveolar parenchyma (Figure 6C and 6E). The immunore-
activity for lymphatic D6 was also increased on Prox1-
immunopositive lymphatic vessels in patients with GOLD
stage IV COPD (Figure 6D and 6F). This increase was re-
stricted to bronchioles and alveolar parenchyma.
Identification of leukocyte-containing lymphatic vessels
As recently described [12], lymphatic vessels were fre-
quently associated with lung lymphoid aggregates. In
addition, across all patient cohorts, lymphatic vesselsFigure 7 Lymphatic vessels co-localize with lymphoid aggregates and c
IV COPD. (A) Lymphatic vessels (brown, arrowheads) frequently co-localized w
revealed that lymphatic vessels (brown) contain (B) CD8-positve T-cells, (C) CD
(E) CD57-positive NK/T-cells. In all sections, nuclei were counterstained with M
visible in (A-E). Ep, bronchiolar epithelium. Scale bars: (A) 50 μm; (B-E) 25 μm.containing luminal mononuclear cells were observed
in all lung compartments, including lymphoid aggre-
gates (Figure 7). In patients with advanced COPD,
several lymphatics were completely filled by cells (exem-
plified in Figure 7A-B and 7E). This finding was almost
absent in control subjects. Double-staining immuno-
histochemistry tentatively identified the luminal cells
(Figure 7B-E). Among the intra-lymphatic leukocytes were
abundant CD8-positive T-cells and CD11c-positive myeloid-
like dendritic cells as well as scattered CD20-positive
B-cells and CD57-positive NK/T-cells. Luminal CD68-
positive monocytes/macrophages were not detected in
the lymphatic vessels.ontain immune cells. (A-E) Micrographs from patients with GOLD stage
ith lymphoid aggregates (LA). Double staining immunohistochemistry
20-positive B-cells, (D) CD11c-positive myeloid-like dendritic cells, and
ayer’s haematoxylin (blue stain). Black endogenous pigment deposition is
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This study reveals the presence and distribution of lymph-
atic vessels in peripheral compartments of human normal
lungs and shows for the first time that in advanced COPD
the most manifest increase in lymphatic numbers takes
place in the alveolar compartment. This study further
shows that in advanced COPD lymphatic vessels exhibit
an altered phenotype characterized by up-regulation of
CCL21 and D6. Considering the role of lymphatics in
transporting leukocytes, these data suggest that lymphatic
vessel changes may have important roles in the immuno-
pathology of patients with severe stages of COPD.
The morphological evaluation of lymphatic vessel
changes in the present study revealed further that the ab-
solute numbers of bronchiolar and arterial wall lymphatic
vessels are increased in lungs of patients with severe
COPD compared with control subjects. However, norma-
lization to tissue area did not reveal a similar increase in
lymphatic vessel numbers. These results suggest that in
these compartments tissue remodelling, such as thicken-
ing of the airway and arterial adventitia, is accompanied
by a proportionally increased formation of lymphatic ves-
sels. In bronchioles lymphatic vessel changes may also in-
volve formation of more folded lymphatic vessels since
the accumulated lymph endothelial length per area unit
was increased in this compartment. The most clear
lymphatic vessel changes were, however, observed in the
alveolar parenchyma, a compartment where under normal
conditions the lymphatics are relatively sparse in numbers.
The present type of morphological lymph vessel
changes, which were most pronounced in advanced
stage COPD, is likely to have several implications for the
immunopathology and pathophysiology observed in this
disease. As COPD becomes severe, inflammatory pro-
cesses are significantly amplified [2]. Thus, the increased
numbers of lymphatic vessels in advanced COPD could
result from an increased demand for clearance of senes-
cent leukocytes and extravasated fluid from the inflamed
peripheral lung regions. The observed increased num-
bers of lymphatic vessels in this and a recent publication
[33] may also reflect an increased demand for trans-
porting activated immune cells from the sites of inflam-
mation to draining lymph nodes. In support of this, this
study reveals that the lymphatic endothelial expression
of the chemokine CCL21 is increased in all peripheral
lung compartments of patients with severe COPD. Among
the major cells expressing the receptor for CCL21 are
antigen-activated dendritic cells [20,37]. In vitro studies
have shown that although CCR7 expression on dendritic
cells may decrease in response to tobacco smoke, their
capacity to migrate towards CCL21 is preserved [38].
Thus, the increased expression of CCL21, which is critical
for the entry of immune cells into the lymphatic vessels,
may facilitate the migration of activated dendritic cells[39] and enhance antigen presentation in draining lymph
nodes. In addition to CCL21, our data also show that the
lymphatic expression of D6 was increased in advanced
COPD. Recent studies have suggested that lymphatic D6,
which scavenges inflammatory CC chemokines, controls
the flow of fluid and migration of appropriate immune
cells to lymph nodes [25]. Previous studies have also dem-
onstrated that D6 is expressed on leukocytes [40]. Interest-
ingly, patients with COPD have increased percentage of
D6-positive alveolar macrophages [41] indicating that D6
may generally be up-regulated in COPD lungs. Even
though D6 is mainly expressed in lymphatic endothelium,
this study confirms previous observations [42] that D6 is
not expressed in all lymphatic vessels. It has been pro-
posed that the lymphatic expression of D6 is up-regulated
by pro-inflammatory cytokines [42]. It is likely that this
mechanism is partly responsible for the presently observed
up-regulation in COPD lungs. Interestingly, the mecha-
nisms of up-regulation may also differ between the
anatomical regions of the lung. For example, in the bron-
chioles almost 100% of the lymphatic vessels expressed D6
already in control lungs. Hence, in this compartment the
increase in total lymph vessels-associated D6 in COPD
may mainly be a consequence of a general increase in
vessel numbers. On the other hand, in the alveolar paren-
chyma where only around 40% of the lymphatic vessels
expressed D6 under baseline conditions, the up-regulation
of D6 immunoreactivity in COPD lungs was also caused
by a significant increase in the proportion of vessels
expressing D6 (which in COPD was increased to around
80%). A similar increased proportion of positive alveolar
lymphatic vessels was also observed for CCL21. Taken
together, the combined action of increased lymphatic
expression of D6 and CCL21 and a general increased
density of lymphatic vessels in COPD lungs is likely to
increase the capacity for regulated trafficking of leukocytes
from the distal parts of the lung to draining lymph nodes.
This study further confirmed a close proximity be-
tween lymphatic vessels and ectopic lung lymphoid ag-
gregates [12,43]. In addition to transporting leukocytes
from the lung to draining lymph nodes, lymphatic
vessels may efficiently transport leukocytes, as well as
antigens, to local lymphoid aggregates in COPD lungs.
Since we observed CCL21-immunoreactive lymphatic
vessels within lymphoid aggregates, one could also
speculate that these lymphatic vessels may offer an im-
portant route for leukocytes to exit from the lymphoid
aggregates. Similar to lymph nodes, the lymphoid
aggregates in COPD lungs contain lymphocytes, fol-
licular dendritic cells and germinal centres [11,13,43]
and are, thus, capable of initiating adaptive immune
responses locally in the lung [44].
The molecular mechanism behind the increased num-
ber of lymphatics in COPD is currently unknown. It is
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may contribute to lymphatic vessel formation by their pro-
duction of lymphangiogenic factors, including VEGF-C
and VEGF-D [32,45,46]. Pro-inflammatory cytokines,
many of which are up-regulated in COPD, such as TNF-α,
can also regulate lymphatic vessel growth [47,48].
At a more upstream level respiratory infections may also
induce the formation of lymphatics. Elegant studies in ani-
mal models of chronic airway inflammation have demon-
strated that lymphangiogenesis, as well as remodelling of
lymphatic vessels, occur extensively in lungs infected with
Mycoplasma pulmonis [32,49]. Although other pathogens
are generally associated with COPD, the majority of
patients with advanced COPD suffer from recurrent infec-
tions of the lower respiratory tract [50] and this may be
one of the driving forces for the presently observed per-
ipheral lymphatic vessel changes in this patient category.
In any case, an expanded lung lymphatic system is likely
to result in a faster clearance of pathogens. Thus, the in-
creased number of lymphatic vessels in major lung com-
partments in COPD may be a double-edged sword; a tool
for accelerated adaptive immune responses in response to
infections, and a structural basis for an aggravated inflam-
mation in COPD lungs.
It is of note that once established an expanded lymph-
atic system may persist for considerable time [32]. Inter-
estingly, after Mycoplasma pulmonis infection, remodelled
blood vessels, in contrast to lymphatics, normalized read-
ily once the underlying inflammation resolved [32]. This
observation suggests that remodelling of the lymphatic
system should be expected to be long lasting and relatively
resistant to anti-inflammatory treatment. This notion is
supported by the fact that lymphatic vessel alterations due
to infections are steroid resistant [49]. In this study
lymphatic vessel changes were most pronounced in pa-
tients who received inhaled corticosteroids indicating that
also in human an expanded lymphatic system may not
normalize readily upon steroid treatment. Future studies
in larger COPD cohorts are, however, warranted to eluci-
date the detailed effects of steroids on newly formed lung
lymphatics.
Although lymphatic vessel changes have been demon-
strated in several lung diseases [33,51], it remains un-
known if de novo formed lymphatics are fully functional
in terms of interstitial fluid clearance. For example,
in vivo animal studies have shown that newly formed
lymphatics in inflammation have an altered structural
phenotype that could impair clearance of fluid [52,53].
Whether or not the increased number of lymphatics in
COPD lungs sufficiently compensates increased plasma
leakage in, for example, an exacerbation remains to be
investigated.
As indicated by this study, the role, extent and type of
lymph vessel change may differ between the differentcompartments of the lung. Indeed, our data suggest that
the relative increase in numbers and activation differed
between bronchioles, vessels and the alveolar paren-
chyma. Unfortunately, our study material did not con-
tain enough pleural material to justify a meaningful
quantitative analysis in this compartment, which nor-
mally is rich in lymphatic vessels. Nevertheless, we did
analyse other microenvironments such as patchy fibrotic
lesions that can be observed in advanced COPD.
Confirming other studies [27,28] our study revealed a
marked increase of lymphatic vessels in fibrotic lesions.
Interestingly, while newly formed lymphatic vessels nor-
mally develop from existing ones through sprouting, in
fibrosis some of the newly formed lymphatic vessels lack
connection to existing lymphatics and may thus have a
different growth pattern [27,28]. Whether similar mech-
anism for growth of lymphatic vessels are active in the
fibrotic lesions that develop in advanced stages of COPD
remains to be investigated.
Although conflicting data exist regarding the presence
of lymphatic vessels in alveolar parenchyma [27,28,54], al-
veolar podoplanin-immunoreactive lymphatic vessels have
been detected in normal human lungs [36,55]. Also in this
study we could observe lymphatic vessels in the alveolar
parenchyma. However, it cannot be excluded that some of
the alveolar lymphatic vessels may be associated with pul-
monary blood vessels not visible by the 2D-projections
provided by conventional histological sections. Also, in
our 2D analysis it cannot be excluded that the increased
numbers of lymphatic vessels may to some extent be
caused by the folding of vessels into complex 3D-
structures. The overall orientation of blood vessels and
bronchioles was in the present study, however, random
and equal among the study groups. Therefore, the pres-
ently observed differences in lymphatic vessel changes are
unlikely a result from biased tissue orientation.
In this study patients with suspected lung cancer were
included. This may be relevant information when investi-
gating lung lymphatic vessels as lymphangiogenesis is of
importance in tumour metastasis [56]. Lung tissue speci-
mens used in this study were, however, obtained as far
away from the tumour as possible in order to minimize
the risk of cancer as potential contributor to the expanded
lymphatic system revealed in COPD. Two factors strongly
argue that this is not the case. Firstly, the patients of our
non-COPD control groups had similar types of solid tu-
mours, suggesting that all differences in the COPD-group
are truly COPD related. Secondly, increased lymphatic
vessel numbers were detected in patients with very severe
COPD who lacked any history of cancer and where the
tissue was collected in association with lung transplant-
ation. As most histological human studies, another limita-
tion of this study was the relatively small study groups, a
factor that we in this study have tried to compensate by
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lung compartments, in each study subject.
Conclusions
In summary, this study demonstrates that in advanced
stages of COPD lymphatic vessels are not only increased
in numbers in the peripheral lung, they are also phenotyp-
ically altered with an increased expression of lymphatic
vessel-associated CCL21 and D6. These novel findings are
suggested to have implications for immune cell traffic in
lungs of patients with advanced stages of COPD.
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